Go to the list of all blogs
Harry Richardson's Avatar
published in Blogs
Nov 18, 2026
TickeronGET DAILY SIGNALS
Orthofix Medical (OFIX) Shares Decline -30% in Past 30 Days Following Guidance Revision

Orthofix Medical (OFIX) Shares Decline -30% in Past 30 Days Following Guidance Revision

Key Takeaways

  • Orthofix Medical (OFIX) shares declined roughly 30% over the past 30 days, falling from about $9.59 to a latest close near $6.67.
  • The drop accelerated after third-quarter 2026 results, when management cut full-year revenue and adjusted EBITDA guidance.
  • U.S. Spine Fixation weakened during the quarter, pressured by distributor exits, unplanned supplier delays, and softer procedural demand.
  • Bright spots included roughly 9% constant-currency growth in Global Limb Reconstruction and early signs of stabilization in U.S. Biologics.
  • Measured over the last three months, the stock is down roughly 36% from mid-August levels near $10.50, extending a longer downtrend.
  • For more detail on valuation, results, and projections, explore OFIX Price Targets, Earnings, and Forecast pages.
  • To see how automated strategies are positioned across the market, explore Trending AI Robots.

Orthofix Medical (OFIX) Company Overview and Market Position

Orthofix Medical Inc. is a global medical technology company focused on advancing healing and restoring mobility for patients with complex musculoskeletal conditions. Headquartered in Lewisville, Texas, the company offers a differentiated portfolio spanning spinal implants, therapeutic solutions such as bone growth stimulators, limb reconstruction and external fixation systems, biologics, and enabling technologies including the 7D FLASH Navigation System.

Orthofix competes in the spine and orthopedic device market, where it positions itself as a technology-enabled partner to surgeons across the continuum of care. Investors follow the stock closely because of its exposure to elective surgical procedure volumes, Medicare reimbursement policy for bone growth stimulators, and the pace of new product adoption such as the VIRATA spinal implant platform. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Orthofix Medical (OFIX) Stock Price Performance: Last 30 Days vs. Quarter

Over the last 30 days, OFIX declined approximately 30%, falling from a closing price of about $9.59 to a latest close near $6.67. The move was not a single-day event but a series of sharp down-legs: the stock pulled back in late October before selling off more aggressively in early November, with the steepest declines surrounding the third-quarter earnings release and guidance revision.

The quarterly picture is even steeper. From mid-August levels near $10.50, the stock has fallen roughly 36%, continuing a broader slide from levels above $12 in early August. The persistent downtrend has taken shares toward the lower end of their 52-week range and reflects a repricing of the company's near-term growth and profitability outlook rather than a brief bout of volatility.

What Drove OFIX Stock Price in the Last 30 Days

The primary catalyst behind the recent decline was the third-quarter 2026 earnings report and accompanying guidance cut. Orthofix reported net sales of $207.9 million, an increase of just 1.1% on a reported basis and 2.3% on a pro forma constant-currency basis, below consensus expectations. The company posted a GAAP net loss of $6.1 million, or $0.15 per share, narrower than the prior-year loss but not enough to offset the top-line disappointment.

Management lowered its full-year 2026 net sales guidance to a range of $825 million to $830 million, down from the prior $845 million to $855 million, and reduced adjusted EBITDA guidance to $86 million to $88 million from $95 million to $98 million. The revision signaled that weakness in the U.S. Spine business—where fixation revenue declined about 5% after growing in the first half—was extending into the fourth quarter.

Investors also reacted to management's explanation of the shortfall: accelerating exits from lower-performing distributors, unplanned supplier delays affecting instruments and interbody products, and softer procedural demand even among top accounts. Concerns about cash generation compounded the move, with cash and equivalents falling to $86.9 million at September 30, 2026, from $104.4 million at June 30, 2026.

What Drove OFIX Stock Performance Over the Last Quarter

The multi-month decline reflects a deeper reassessment of Orthofix's growth trajectory. After a promising second quarter in which Global Spine Fixation grew and management highlighted improving execution, third-quarter results revealed that the company's largest business, U.S. Spine, had stalled amid channel consolidation and supply disruptions.

The broader narrative shifted from an early-stage turnaround to a recovery plan still in progress. Strength in Global Limb Reconstruction—which grew roughly 9% in constant currency to $36.4 million, led by FitBone and TrueLok Elevate—and stabilizing U.S. Biologics provided offsets but were not enough to counter the spine headwinds. The guidance reset, combined with a leveraged balance sheet and negative free cash flow, has kept sentiment cautious and pressured the valuation.

OFIX Stock Forecast Drivers: What Investors Should Watch Next

Looking ahead, investors are likely to focus on whether the U.S. Spine business stabilizes as distributor exits and supplier constraints are resolved. The planned full market launch of the VIRATA spinal implant system in the fourth quarter is a key product catalyst, alongside continued adoption of the 7D navigation platform, which received additional 510(k) clearances during the quarter.

Other factors to monitor include the pace of U.S. Biologics recovery, the trajectory of limb reconstruction growth, Medicare reimbursement dynamics for bone growth stimulators, and progress toward positive free cash flow. Macroeconomic variables such as hospital capital spending, elective procedure volumes, and foreign exchange movements also matter. These are informational considerations rather than investment recommendations, and outcomes will depend on execution against the company's revised guidance.

Reviewing AI-Driven Strategies for Context

I frequently turn to Tickeron’s AI Trading Bots when assessing how automated systems are positioned around names like OFIX. The platform lets users compare a range of rules-based approaches across different timeframes and risk profiles, which can offer an additional lens on market sentiment without replacing fundamental analysis. It is one of several tools I reference to round out my own research process.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: OFIX

Contributor

Harry Richardson — Algorithmic Trader & Strategy Developer Harry is an algorithmic trader specializing in impulse and breakout trading strategies across cryptocurrency and equity markets. With more than 10 years of experience in developing automated trading systems, he focuses on building structured algorithms designed to capture momentum while maintaining strict risk control. His approach combines quantitative analysis, real-market execution, and continuous performance monitoring. Vitalii prioritizes risk management, drawdown control, and strategy stability over short-term optimization, ensuring algorithms are adaptable to changing market conditions. He has developed and tested hundreds of automated strategies, working extensively with live trading environments, forward testing, and portfolio-level algorithm management. His work centers on transforming trading ideas into fully operational, scalable automated systems.


OFIX in -6.97% downward trend, sliding for three consecutive days on November 17, 2026

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where OFIX declined for three days, in 246 of 309 cases, the price declined further within the following month. The odds of a continued downward trend are 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on October 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on OFIX as a result. In 64 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 74%.

The Moving Average Convergence Divergence Histogram (MACD) for OFIX turned negative on November 02, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 53 similar instances when the indicator turned negative. In 42 of the 53 cases the stock turned lower in the days that followed. This puts the odds of success at 79%.

OFIX moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for OFIX crossed bearishly below the 50-day moving average on November 06, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 18 of 23 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 78%.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +11.09% 3-day Advance, the price is estimated to grow further. Considering data from situations where OFIX advanced for three days, in 202 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 71%.

OFIX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 104 of 149 cases where OFIX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 70%.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 15 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. OFIX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 94 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of 98 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.747) is normal, around the industry mean (4.142). P/E Ratio (-5.178) is within average values for comparable stocks, (3.291). OFIX's Projected Growth (PEG Ratio) (48.825) is slightly higher than the industry average of (11.253). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.431) is also within normal values, averaging (40.124).

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OFIX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

Notable companies

The most notable companies in this group are Abbott Laboratories (NYSE:ABT), Medtronic plc (NYSE:MDT), Boston Scientific Corp (NYSE:BSX), Edwards Lifesciences Corp (NYSE:EW).

Industry description

The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.

Market Cap

The average market capitalization across the Medical/Nursing Services Industry is 6.17B. The market cap for tickers in the group ranges from 837 to 190.22B. ABT holds the highest valuation in this group at 190.22B. The lowest valued company is DHAI at 837.

High and low price notable news

The average weekly price growth across all stocks in the Medical/Nursing Services Industry was -9%. For the same Industry, the average monthly price growth was -9%, and the average quarterly price growth was -14%. POAS experienced the highest price growth at 172%, while LFWD experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Medical/Nursing Services Industry was -44%. For the same stocks of the Industry, the average monthly volume growth was -3% and the average quarterly volume growth was -49%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 48
P/E Growth Rating: 50
Price Growth Rating: 62
SMR Rating: 89
Profit Risk Rating: 94
Seasonality Score: 14 (-100 ... +100)
Paper Trades 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a developer of surgical products to the spine and orthopedic markets

Industry MedicalNursingServices

Industry
Medical Specialties
Address
3451 Plano Parkway
Phone
+1 214 937-2000
Employees
1605
Web
https://www.orthofix.com
Interact to see
Advertisement
UNH dropped -7.80% to $359.29 from Tuesday's $389.68 close, extending a two-session decline to roughly -13% and touching its lowest level in about seven weeks; the move occurred during regular market hours. The selloff accelerated on the CMS "CRUSH" proposal unveiled Nov. 16, which would extrapolate Medicare Advantage risk-adjustment audit findings from samples across entire contracts back to payment year 2018 and drop the fee-for-service adjuster; CMS estimates roughly $9 billion in industry clawbacks per payment year, and UnitedHealth, the largest MA insurer, has not sized its exposure.
SAP's U.S. shares fell from Monday's close of $233.83 to $221.99 by late Tuesday morning in New York, a -5.06% decline recorded during regular trading hours. The company-specific trigger was the announced exit of Chief Customer Officer Thomas Saueressig, an executive board member since 2019, who will leave at the end of March 2027 to become CEO of IONOS; the disclosure came before the U.S. open.
Different growth engines: MRVL is riding accelerating AI data-center demand for custom chips and networking, while QCOM remains heavily tied to a soft smartphone market. Momentum contrast: Marvell's data-center revenue guidance has strengthened, whereas Qualcomm's near-term outlook has been pressured by memory-supply constraints and shrinking handset volumes.
TMC fell from Monday's $2.11 close to $1.96 by 10:10 a.m. ET, a -7.11% decline that occurred entirely in the regular session after an early premarket gain faded. No verified news or fundamental catalyst found for the drop; the move is likely technical, extending the post-Q3 unwind that followed NOAA pushing its certification decision to mid-December, with the stock averaging a 4.0% daily swing and logging 11 sessions of 7%-or-larger moves in the last 60.
IonQ slid from Monday's close of $26.45 to $24.73 on Tuesday, a -6.50% move that unfolded during regular trading hours after modest premarket gains faded. The decline was sector-driven rather than company-specific: quantum and AI-adjacent speculative names extended a multi-session liquidation ahead of Nvidia's quarterly report, with unease over Nvidia's abrupt CEO transition keeping risk appetite weak.